Yanda Lu

The Department of Oncology, The First Affiliated Hospital of Hainan Medical University

Affiliated withThe First Affiliated Hospital of Hainan Medical University

Research Area

Biography

Yanda Lu has not added Biography.
If you are Yanda Lu and would like to personalize this page please email our Author Liaison for assistance.

JoVE Journal Publications

ArticleTotal : 1	Year
Publication title	2026

Other Publications

Article	Year
MicroRNA-374b inhibits liver cancer progression via down regulating programmed cell death-1 expression on cytokine-induced killer cells. Oncology letters\| PubMed ID: 29552119	2018
Long noncoding RNA OR3A4 promotes the proliferation and invasion of osteosarcoma cells by sponging miR-1227-5p. Journal of bone oncology\| PubMed ID: 32082982	2020
Bioinformatical Analysis of Gene Expression Omnibus Database Associates TAF7/CCNB1, TAF7/CCNA2, and GTF2E2/CDC20 Pathways with Glioblastoma Development and Prognosis. World neurosurgery\| PubMed ID: 32147549	2020
Repurposing antitussive benproperine phosphate against pancreatic cancer depends on autophagy arrest. Molecular oncology\| PubMed ID: 33226737	2021
Computed Tomography-Guided Percutaneous Radiofrequency Ablation in Older Adults With Early-Stage Peripheral Lung Cancer: A Retrospective Cohort Study. Cancer control : journal of the Moffitt Cancer Center\| PubMed ID: 35076322	2022
Comprehensive Analysis of the Carcinogenic Process, Tumor Microenvironment, and Drug Response in HPV-Positive Cancers. Frontiers in oncology\| PubMed ID: 35392231	2022
Molecular characterization of matrix metalloproteinase gene family across primates. Aging\| PubMed ID: 35444067	2022
Determining the Optimal Cut-Off Values of Serum E2 and FSH for Evaluating the Menopausal Status of Breast Cancer Patients in a Southern Chinese Population. Disease markers\| PubMed ID: 36046380	2022
Comprehensive analysis of expression and prognostic value in kidney renal papillary cell carcinoma and clear cell carcinoma. Frontiers in molecular biosciences\| PubMed ID: 36188228	2022
Validation of different personalized risk models of chemotherapy-induced nausea and vomiting: results of a randomized, double-blind, phase III trial of fosaprepitant for cancer patients trea... Cancer communications (London, England)\| PubMed ID: 36545810	2023
CEACAM1 Is a Prognostic Biomarker and Correlated with Immune Cell Infiltration in Clear Cell Renal Cell Carcinoma. Disease markers\| PubMed ID: 36712923	2023
Integrated analysis of the relation to tumor immune microenvironment and predicted value of Stonin1 gene for immune checkpoint blockage and targeted treatment in kidney renal clear cell carc... BMC cancer\| PubMed ID: 36759775	2023
A novel CTLA-4 blocking strategy based on nanobody enhances the activity of dendritic cell vaccine-stimulated antitumor cytotoxic T lymphocytes. Cell death & disease\| PubMed ID: 37419930	2023
Construction of a ceRNA network to reveal a vascular invasion associated prognostic model in hepatocellular carcinoma. Open medicine (Warsaw, Poland)\| PubMed ID: 37724126	2023
HIF-1α-mediated LAMC1 overexpression is an unfavorable predictor of prognosis for glioma patients: evidence from pan-cancer analysis and validation experiments. Journal of translational medicine\| PubMed ID: 38678297	2024
Hypoxia-driven lncRNA CTD-2510F5.4: a potential player in hepatocellular carcinoma's prognostic stratification, cellular behavior, tumor microenvironment, and therapeutic response. Molecular biology reports\| PubMed ID: 39133347	2024
Randomized, Phase III Trial of Mixed Formulation of Fosrolapitant and Palonosetron (HR20013) in Preventing Cisplatin-Based Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: PROFIT. Journal of clinical oncology : official journal of the American Society of Clinical Oncology\| PubMed ID: 39621965	2025
ALYREF stabilizes CREPT mRNA to accelerate the development of nasopharyngeal carcinoma through dependence on m5C modification. Experimental cell research\| PubMed ID: 40925509	2025